Butyrate Gut Microbiome Meta-analysis: What the Evidence Says

Quick Answer

Butyrate Gut Microbiome Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Most existing reviews either describe mechanistic pathways without systematically evaluating clinical evidence quality, or report clinical findings without grounding them in the mechanistic architecture of the axis. [Jiang Changsheng (2026); evidence level 3]
• As a result, there remains a substantial gap between experimental insights and their incorporation into evidence-based therapeutic strategies. [Jiang Changsheng (2026); evidence level 3]
• Beyond these classical risk factors, gut microbiota dysbiosis is an established contributor to the pathogenesis of both disorders. [Barakat Hassan (2026); evidence level 3]
• In particular, reduced microbial diversity and loss of beneficial taxa are associated with impaired intestinal barrier function, metabolic endotoxemia, chronic low-grade inflammation, and disrupted energy homeostasis, all of which favor insulin resistance and adiposity. [Barakat Hassan (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For butyrate gut microbiome meta-analysis, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Jiang Changsheng (2026). Unraveling the gut microbiota-brain axis: Mechanisms, pathophysiology, and therapeutic opportunities. DOI: 10.1016/j.isci.2026.116224. PMCID: PMC13266037. PMID: 42305614. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13266037/
• Barakat Hassan (2026). Probiotic Modulation of Gut Microbiota: Antioxidant Mechanisms and Clinical Benefits in Obesity and Type 2 Diabetes Management. DOI: 10.3390/antiox15060727. PMCID: PMC13295857. PMID: 42352033. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13295857/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.